During the past decade, National Cancer Center Hospital East conducted 237 clinical trials. In the 10-year time frame, 237 clinical trials started and 65 clinical trials were completed, i.e. on average, 27.4% percent of trials that started reached the finish line to date. In the past 5 years, 140 clinical trials started and 43 clinical trials were completed. i.e. 30.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Cancer Center Hospital East" #1 sponsor was "Pfizer" with 35 trials, followed by "Hoffmann-La Roche" with 27 trials sponsored, "Amgen" with 23 trials sponsored, "Boehringer Ingelheim" with 16 trials sponsored and "Daiichi Sankyo, Inc." with 16 trials sponsored. Other sponsors include 169 different institutions and companies that sponsored additional 72 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Cancer Center Hospital East" #1 collaborator was "AstraZeneca" with 15 trials as a collaborator, "Merck Sharp & Dohme LLC" with 12 trials as a collaborator, "Ministry of Health, Labour and Welfare, Japan" with 11 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 10 trials as a collaborator and "Eli Lilly and Company" with 8 trials as a collaborator. Other collaborators include 76 different institutions and companies that were collaborators in the rest 64 trials.

According to Clinical.Site data, the most researched conditions in "National Cancer Center Hospital East" are "Neoplasms" (18 trials), "Carcinoma, Non-Small-Cell Lung" (17 trials), "Non-Small Cell Lung Cancer" (13 trials), "Solid Tumors" (13 trials) and "Gastric Cancer" (11 trials). Many other conditions were trialed in "National Cancer Center Hospital East" in a lesser frequency.

Most popular intervention types in "National Cancer Center Hospital East" are "Drug" (277 trials), "Biological" (20 trials), "Other" (11 trials), "Procedure" (8 trials) and "Device" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (36 trials), "Pembrolizumab" (28 trials), "Carboplatin" (21 trials), "Cisplatin" (20 trials) and "Atezolizumab" (19 trials). Other intervention names were less common.

The vast majority of trials in "National Cancer Center Hospital East" are 263 trials for "All" genders, 15 trials for "Female" genders and 12 trials for "Male" genders.

Currently, there are NaN active trials in "National Cancer Center Hospital East". undefined are not yet recruiting, 100 are recruiting, 84 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 81 completed trials in National Cancer Center Hospital East, undefined suspended trials, and 19 terminated clinical trials to date.

Out of the total trials that were conducted in National Cancer Center Hospital East, 108 "Phase 1" clinical trials were conducted, 82 "Phase 2" clinical trials and 120 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".